Elekta Appoints New CEO to Drive Growth and Profitability in Radiotherapy Market

Elekta, a leading player in the cancer radiotherapy market, has announced the appointment of Jakob Just-Bomholt as its new president and CEO, effective September 1, 2025. This strategic move comes as the Stockholm-based company seeks to improve profitability and drive global expansion in the competitive radiotherapy sector.

Leadership Transition and Strategic Goals

Just-Bomholt, formerly the CEO of Danish digital dental scanning firm 3Shape, brings a wealth of experience to his new role at Elekta. The company's founder and chairman, Laurent Leksell, cited Just-Bomholt's strategic leadership, international experience, and ability to drive profitable growth as key factors in his selection.

The appointment follows a decision made in March by Elekta's board to seek new leadership to enhance the company's performance. Just-Bomholt will take over from interim CEO Jonas Bolander, who has focused on stabilizing and simplifying the business during the transition period.

Market Challenges and Opportunities

Elekta faces significant challenges in key markets, particularly in the United States and China. In the U.S., the company is eagerly awaiting the launch of its new Evo radiation therapy machine, which has already contributed to a 3% global sales growth in Europe. However, the U.S. launch has been delayed due to regulatory hurdles.

In China, Elekta's sales have been impacted by the ongoing anti-corruption drive. Despite these challenges, the company sees opportunities for growth, particularly in Europe where the Evo machine has gained traction.

Regulatory and Product Development Updates

Elekta recently made a strategic shift in its approach to obtaining U.S. Food and Drug Administration (FDA) clearance for the Evo system. The company withdrew its initial filing and is in the process of resubmitting its application with a greater focus on cybersecurity to better align with the FDA's approval process.

Interim CEO Bolander stated during a recent earnings call that this change in filing strategy is expected to have a "limited" impact on the overall product launch timeline. The company remains optimistic about Evo's potential to strengthen its position in the global radiotherapy market, where it competes with Siemens Healthineers' Varian.

As Jakob Just-Bomholt prepares to take the helm at Elekta, the industry will be watching closely to see how he navigates these challenges and capitalizes on emerging opportunities in the evolving landscape of cancer radiotherapy.